David C Habiger bought $251K of Boston Scientific (BSX)
Executed May 19, disclosed May 21, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 21), the stock returned -20.9% (delay-adjusted); from the execution session (May 19), -20.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
David C Habiger (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Boston Scientific Corporation (BSX). Across 1 priced purchase filing, the average 21-session return was -20.4% from execution and -20.9% from disclosure (delay-adjusted; derived). The largest single filing was $251K of BSX (4,450 sh across 2 lots, as filed), executed May 19.
Healthcare · Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties wor…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→